Midday Report: Rhythm (RYTM) Trades Higher June 22

Equities Staff  |

Today Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is trading 5.48% up.

The latest price, as of 12:10:00 est, was $4.42. Rhythm has risen $0.23 in trading today.

431,892 shares have exchanged hands.

As of the previous close, Rhythm has moved YTD 57.92%. The company is set to release earnings on 2022-08-02.

For technical charts, analysis, and more on Rhythm visit the company profile.

About Rhythm Pharmaceuticals Inc.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.

To get more information on Rhythm Pharmaceuticals Inc. and to follow the company's latest updates, you can visit the company's profile page here: Rhythm Pharmaceuticals Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets



Market Movers

Sponsored Financial Content